{"name":"Mehdi Hamadani","slug":"mehdi-hamadani","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQdloydmJfbEc1MlhsU3JRcklib0lxZWlWYzhNYmxnajdLeHp5WHBaUnRZVlN2UXRuS2tYY2ZvV0lHdklVaFlOUjQ4WmNnSW1IYmxseE5LaXRITzdqX01tWTNGQ3E5UFp4RTM1aWVxclBFTzdaSDBMdnl1cUNCZVlWU0dJTjh4Z25iemtnNVFtaS0xbHZG?oc=5","date":"2025-11-03","type":"trial","source":"The Pharma Letter","summary":"Caribou Bio leaps on early data for vispa-cel - The Pharma Letter","headline":"Caribou Bio leaps on early data for vispa-cel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTFB1dWlqR2lkZ2VyeV8yQXhyMzFfQkdkeGQ4V2xzeF81Y25DQXVacVEzcXg4YVRmMENaUW9TX3FpeGdGQjg5QXRHaG5oaUxJUUNBS04yYkx6VWpEYmR6cVdWRkV6MA?oc=5","date":"2025-08-11","type":"pipeline","source":"Wiley Online Library","summary":"CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis - Wiley Online Library","headline":"CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE0xc0ZoTGxyeUROLUlQTjBBZVRQUGZrRlppZEJyV2pBTWJzdTlOY0xQREJDeUZtNENOVV96Z2I4RTZqYlI5djlUWmk4cHEzdWhHVXRJS1NUTzdtV1pKa1c0NVNBanVkQ29l?oc=5","date":"2025-07-22","type":"pipeline","source":"Wiley Online Library","summary":"Chimeric antigen receptor T‐cell therapy for high‐grade B‐cell lymphoma NOS - Wiley Online Library","headline":"Chimeric antigen receptor T‐cell therapy for high‐grade B‐cell lymphoma NOS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE13ZkFSak1QbUx2RjhnU2xNVlBmbVFfX3VvdFJKT0NjV2xnWUVyTmVndE81Qno5LVJpSWFta0dmc2o3WTQtOUh0LWhjdUxaVFdoUWdhRFUycGdycU83MWdrUw?oc=5","date":"2023-06-21","type":"pipeline","source":"NEJM","summary":"Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis - NEJM","headline":"Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9QeUxzZ3lsSDRXZzJ5d2pVcDlZTGdOMkJ3Y3d3RTRQTXVrR3U2aTF4SzFYNXotX1FibXJsSlFLdXRQaHBDY2RpQmJXOE14V2E0Tm5Dc3J4N2plbzFJWVllWERVaU5OM3owYjlBa3lWU1poWVBLbHVtZjBQTQ?oc=5","date":"2020-03-10","type":"regulatory","source":"Wiley","summary":"Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled tri","headline":"Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9XbUdZTnQ1dTFTb1o0MFBjNGtXanpHTkZQOS1HTmpBcDZTS2tjcGFZSDYyZ3RabEZpaEx5c1FXakJJckR4OGxqX1pyVm1DSXhCLWFxWXZEUUwwMllMZHc?oc=5","date":"2019-12-03","type":"pipeline","source":"Nature","summary":"Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis - Nature","headline":"Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}